search
Back to results

Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device. (DESERVE)

Primary Purpose

Carotid Artery Disease, Stroke Prevention

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Carotid artery stenting
Sponsored by
Invatec S.p.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Carotid Artery Disease focused on measuring carotid artery stenting, cerebral protection, stroke, ischemic lesion, DW-MRI

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. ≥ 18 years old;
  2. Eligibility for carotid artery revascularization;
  3. A significant stenosis in symptomatic patients with ≥ 50% Diameter Stenosis (%DS) or asymptomatic ≥ 80 %DS as defined by angiography.

    Symptomatic is defined as a carotid artery stenosis associated with ipsilateral TIA, amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment.

  4. Suitable clinical conditions to perform DW-MRI.
  5. Written informed consent as approved by the Ethics Committee of the respective clinical site.

Exclusion Criteria:

  1. Female with childbearing potential without a negative pregnancy test.
  2. Life-expectancy less than 6 months.
  3. Underlying disease of the carotid artery other than atherosclerosis (e.g. vasculitis, traumatic dissection, fibromuscular dysplasia).
  4. Prior stenting in the target vessel;
  5. Patients with chronic or re-current atrial fibrillation.
  6. Patient has had a Myocardial Infarction within 72 hours prior to the procedure.
  7. Patient experienced a stroke within 4 weeks prior to the procedure.
  8. History of severe disabling stroke according to the modified Rankin scale > 4.
  9. Severe renal failure (serum creatinine > 2.0 mg/dL).
  10. Severe peripheral arterial occlusive disease, which might impede a safe introduction of a 9F-sheath for the use of a Mo.Ma-device.
  11. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Statins, Heparin, Nitinol, contrast agents (that cannot be adequately pre-medicated).
  12. Patient currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the DESERVE study endpoints.
  13. Any planned major surgery within 30 days after the study procedure.
  14. In the investigators opinion patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.

    Angiographic exclusion criteria:

  15. Totally occluded internal carotid artery considered as the target vessel.
  16. Multiple internal carotid artery stenoses or lesion longer than 4 cm (whichever occurs) that cannot be covered by one (1) stent.
  17. Severe ostial stenosis of the common carotid artery.
  18. The presence of ipsilateral intracranial stenosis that requires treatment.
  19. Contralateral occlusion of the internal carotid arteries associated with a poor collateral flow through the circle of Willis.
  20. An aortic arch anatomical complexity that may preclude the safe placement of the Mo.Ma device including particularly, the impossibility to navigate a stiff guide wire into the external carotid artery.

Sites / Locations

  • CardioVascular Center Frankfurt, Sankt Katharinen
  • Heart Center Leipzig, Clinical and Interventional Angiology
  • Casa di Cura Privata "Montevergine" S.p.A.
  • Gruppo Villa Maria, Villa Maria Cecilia Hospital
  • Ospedale Civile di Mirano, Unità di Cardiologia
  • Jagellonian University, College of Medicine, Institute of Cardiology, University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.

Outcomes

Primary Outcome Measures

The de-novo occurrence of intra-cerebral lesions per patient by comparing baseline (within 1 week prior procedure) and post-procedural DW-MRI (from 3 to 12 hours post procedure).

Secondary Outcome Measures

Device Success; Technical Success; Procedural Success; Restenosis rate at 30 days follow up; TLR at 30 days follow up; Access Site Complications; MACCE at 30 days; Incidence of TIA up to 30 days.

Full Information

First Posted
November 25, 2008
Last Updated
March 14, 2016
Sponsor
Invatec S.p.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT00798512
Brief Title
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
Acronym
DESERVE
Official Title
DESERVE: Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device. A Prospective, Multicenter Study.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
March 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Invatec S.p.A.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to detect new ischemic lesions after carotid artery stenting (with the Cristallo Ideale stent), in patients with high grade carotid artery stenosis, by diffusion-weighted magnetic resonance imaging (DW-MRI), using the endovascular proximal flow blockage (Mo.Ma device) for cerebral protection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carotid Artery Disease, Stroke Prevention
Keywords
carotid artery stenting, cerebral protection, stroke, ischemic lesion, DW-MRI

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
127 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
Intervention Type
Device
Intervention Name(s)
Carotid artery stenting
Intervention Description
The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure. For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal).
Primary Outcome Measure Information:
Title
The de-novo occurrence of intra-cerebral lesions per patient by comparing baseline (within 1 week prior procedure) and post-procedural DW-MRI (from 3 to 12 hours post procedure).
Time Frame
3-12 hours after index procedure
Secondary Outcome Measure Information:
Title
Device Success; Technical Success; Procedural Success; Restenosis rate at 30 days follow up; TLR at 30 days follow up; Access Site Complications; MACCE at 30 days; Incidence of TIA up to 30 days.
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥ 18 years old; Eligibility for carotid artery revascularization; A significant stenosis in symptomatic patients with ≥ 50% Diameter Stenosis (%DS) or asymptomatic ≥ 80 %DS as defined by angiography. Symptomatic is defined as a carotid artery stenosis associated with ipsilateral TIA, amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment. Suitable clinical conditions to perform DW-MRI. Written informed consent as approved by the Ethics Committee of the respective clinical site. Exclusion Criteria: Female with childbearing potential without a negative pregnancy test. Life-expectancy less than 6 months. Underlying disease of the carotid artery other than atherosclerosis (e.g. vasculitis, traumatic dissection, fibromuscular dysplasia). Prior stenting in the target vessel; Patients with chronic or re-current atrial fibrillation. Patient has had a Myocardial Infarction within 72 hours prior to the procedure. Patient experienced a stroke within 4 weeks prior to the procedure. History of severe disabling stroke according to the modified Rankin scale > 4. Severe renal failure (serum creatinine > 2.0 mg/dL). Severe peripheral arterial occlusive disease, which might impede a safe introduction of a 9F-sheath for the use of a Mo.Ma-device. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Statins, Heparin, Nitinol, contrast agents (that cannot be adequately pre-medicated). Patient currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the DESERVE study endpoints. Any planned major surgery within 30 days after the study procedure. In the investigators opinion patient has a severe co-morbid condition(s) that could limit the ability to participate in the study. Angiographic exclusion criteria: Totally occluded internal carotid artery considered as the target vessel. Multiple internal carotid artery stenoses or lesion longer than 4 cm (whichever occurs) that cannot be covered by one (1) stent. Severe ostial stenosis of the common carotid artery. The presence of ipsilateral intracranial stenosis that requires treatment. Contralateral occlusion of the internal carotid arteries associated with a poor collateral flow through the circle of Willis. An aortic arch anatomical complexity that may preclude the safe placement of the Mo.Ma device including particularly, the impossibility to navigate a stiff guide wire into the external carotid artery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giancarlo Biamino, MD
Organizational Affiliation
Gruppo Villa Maria - Endovascular Villa Maria Cecilia Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
CardioVascular Center Frankfurt, Sankt Katharinen
City
Frankfurt
ZIP/Postal Code
60389
Country
Germany
Facility Name
Heart Center Leipzig, Clinical and Interventional Angiology
City
Leipzig
ZIP/Postal Code
04289
Country
Germany
Facility Name
Casa di Cura Privata "Montevergine" S.p.A.
City
Mercogliano
State/Province
Avellino
ZIP/Postal Code
83013
Country
Italy
Facility Name
Gruppo Villa Maria, Villa Maria Cecilia Hospital
City
Cotignola
State/Province
RA
ZIP/Postal Code
48010
Country
Italy
Facility Name
Ospedale Civile di Mirano, Unità di Cardiologia
City
Mirano
ZIP/Postal Code
30035
Country
Italy
Facility Name
Jagellonian University, College of Medicine, Institute of Cardiology, University Hospital
City
Krakow
ZIP/Postal Code
31-501
Country
Poland

12. IPD Sharing Statement

Learn more about this trial

Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.

We'll reach out to this number within 24 hrs